NAMA
VERV

Nikko Asset Management Americas’s Verve Therapeutics VERV Stock Holding History

Nikko Asset Management Americas’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,115,466
Closed -$5.43M – 193
2024
Q2 		$5.43M Sell
1,115,466
-1,476,732
-57% -$9.28M 0.06% 100
2024
Q1 		$34.3M Buy
2,592,198
+194,594
+8% +$2.58M 0.34% 55
2023
Q4 		$33.3M Buy
2,397,604
+250,361
+12% +$3.1M 0.32% 55
2023
Q3 		$28.4M Sell
2,147,243
-38,614
-2% -$622K 0.34% 54
2023
Q2 		$40.9M Buy
2,185,857
+587,863
+37% +$9.79M 0.43% 48
2023
Q1 		$22.4M Buy
1,597,994
+369,547
+30% +$7.24M 0.26% 54
2022
Q4 		$23.8M Buy
1,228,447
+452,750
+58% +$12M 0.34% 53
2022
Q3 		$24.4M Buy
775,697
+660,465
+573% +$21.1M 0.31% 58
2022
Q2 		$1.49M Buy
115,232
+49,123
+74% +$761K 0.02% 173
2022
Q1 		$1.32M Sell
66,109
-4,841
-7% -$138K 0.01% 181
2021
Q4 		$2.27M Sell
70,950
-7,471
-10% -$314K 0.01% 159
2021
Q3 		$3.61M Buy
+78,421
New +$4.61M 0.02% 150

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Nikko Asset Management Americas's VERV Position: Q3 2024 in Review

Nikko Asset Management Americas sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 1,115,466 shares — an estimated $5.43M sold.

Nikko Asset Management Americas first reported a position in VERV in Q3 2021 and held it in 12 quarters. The position peaked at $40.9M in Q2 2023. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Nikko Asset Management Americas reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Nikko Asset Management Americas sold 1,115,466 Verve Therapeutics shares in Q3 2024, an estimated $5.43M.
  • Nikko Asset Management Americas first reported a position in Verve Therapeutics in Q3 2021 and held it in 12 quarters.
  • Nikko Asset Management Americas's Verve Therapeutics position peaked at $40.9M in Q2 2023.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on Nikko Asset Management Americas's 13F filing for Q3 2024, filed 7 Nov 2024.